维利帕尼联合同步胸壁及区域淋巴结放疗治疗炎性或局部复发乳腺癌:TBCRC 024 I期多中心研究
这项I期多中心研究在30例完全手术切除后的炎性或局部复发乳腺癌患者中,评估维利帕尼联合同步胸壁及区域淋巴结放疗(50 Gy加10 Gy推量)的剂量递增与安全性。采用贝叶斯时间-事件持续重评估方法,以30%目标剂量限制性毒性率递增四个剂量水平。结果显示最高测试剂量下严重急性毒性未超过30%,但3年时近半数存活患者出现3级不良事件,强调长期毒性监测的重要性。
要点
- 维利帕尼联合同步胸壁及区域淋巴结放疗在最高测试剂量下严重急性毒性未超过30%
- 5例剂量限制性毒性包括4例湿性脱屑和1例中性粒细胞减少
- 3年时15例存活患者中6例出现治疗野严重纤维化
核心结论
- 尽管最高测试剂量下严重急性毒性未超过30%,但3年时近半数存活患者出现3级不良事件,强调放疗增敏剂试验中长期毒性监测的重要性。
研究设计与样本
- 多机构I期研究,纳入30例完全手术切除后的炎性或局部复发乳腺癌患者,接受维利帕尼联合同步胸壁及区域淋巴结放疗。
- 放疗为胸壁及区域淋巴结50 Gy加10 Gy推量。
- 采用贝叶斯时间-事件持续重评估方法递增四个剂量水平,目标剂量限制性毒性率为30%,评估期为6周治疗加4周随访。
主要发现
- 共发生5例剂量限制性毒性:4例为湿性脱屑(100 mg每日两次和150 mg每日两次各2例),1例为中性粒细胞减少(200 mg每日两次)。
- 任何级别3级毒性(不论归因)的粗率为第1年10%、第2年16.7%、第3年46.7%。
- 第3年时,15例存活患者中6例出现治疗野严重纤维化。
关键数值与推荐
- 剂量限制性毒性定义包括:融合性湿性脱屑>100 cm2、非血液学毒性≥3级、需延迟放疗>1周的毒性、中性粒细胞绝对值<1,000/mm3、血小板<50,000/mm3、或血红蛋白<8.0 g/dL(若与研究治疗可能、很可能或肯定相关)。
临床怎么用
- 维利帕尼联合同步胸壁及区域淋巴结放疗在测试剂量下急性毒性可接受,但需长期监测晚期毒性如纤维化。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Locoregional control for inflammatory breast cancers and chest wall recurrences is suboptimal, which has motivated interest in radiosensitization to intensify therapy. Preclinical studies have suggested a favorable therapeutic index when poly (ADP-ribose) polymerase inhibitors are used as radiosensitizers; clinical investigation is necessary to establish appropriate dosing and confirm safety. Patients and Methods We conducted a multi-institutional phase I study of veliparib and concurrent radiotherapy (RT) to the chest wall and regional lymph nodes in 30 patients with inflammatory or locally recurrent breast cancer after complete surgical resection. RT consisted of 50 Gy to the chest wall and regional lymph nodes plus a 10-Gy boost. A Bayesian time-to-event continual reassessment method escalated dose through four levels, with a 30% targeted rate of dose-limiting toxicity (DLT) measured during the 6 weeks of treatment plus 4 weeks of follow-up. DLTs were defined as confluent moist desquamation > 100 cm2, nonhematologic toxicity grade ≥ 3, toxicity that requires an RT dose delay > 1 week, absolute neutrophil count < 1,000/mm3, platelet count < 50,000/mm3, or hemoglobin < 8.0 g/dL if possibly, probably, or definitely related to study treatment. Results Five DLTs occurred: Four were moist desquamation (two each at 100 and 150 mg twice a day), and one was neutropenia (at 200 mg twice a day). The crude rate of any grade 3 toxicity (regardless of attribution) was 10% at year 1, 16.7% at year 2, and 46.7% at year 3. At year 3, six of 15 surviving patients had severe fibrosis in the treatment field. Conclusion Although severe acute toxicity did not exceed 30% even at the highest tested dose, nearly half of surviving patients demonstrated grade 3 adverse events at 3 years, which underscores the importance of long-term monitoring of toxicity in trials of radiosensitizing agents.
引用
- Jagsi R, Griffith KA, Bellon JR, et al. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018. PMID: 29558281. doi:10.1200/JCO.2017.77.2665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。